Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone–induced osteoclastogenesis
Umeå University, Faculty of Medicine, Department of Odontology.
Show others and affiliations
2019 (English)In: The FASEB Journal, ISSN 0892-6638, E-ISSN 1530-6860, Vol. 33, no 12, p. 14394-14409Article in journal (Refereed) Published
Abstract [en]

Glucocorticoid (GC) therapy decreases bone mass and increases the risk of fractures. We investigated interactions between the GC dexamethasone (DEX) and the bone resorptive agents 1,25(OH)2-vitamin D3 (D3) and parathyroid hormone (PTH) on osteoclastogenesis. We observed a synergistic potentiation of osteoclast progenitor cell differentiation and formation of osteoclasts when DEX was added to either D3- or PTH-treated mouse bone marrow cell (BMC) cultures. Cotreatment of DEX with D3 or PTH increased gene encoding calcitonin receptor (Calcr), acid phosphatase 5, tartrate resistant (Acp5), cathepsin K (Ctsk), and TNF superfamily member 11 (Tnfsf11) mRNA, receptor activator of NF-κB ligand protein (RANKL), numbers of osteoclasts on plastic, and pit formation and release of C-terminal fragment of type I collagen from cells cultured on bone slices. Enhanced RANKL protein expression caused by D3 and DEX was absent in BMC from mice in which the GC receptor (GR) was deleted in stromal cells/osteoblasts. Synergistic interactions between DEX and D3 on RANKL and osteoclast formation were present in BMC from mice with attenuated GR dimerization. These data demonstrate that the GR cooperates with D3 and PTH signaling, causing massive osteoclastogenesis, which may explain the rapid bone loss observed with high dosages of GC treatment.

Place, publisher, year, edition, pages
Federation Amer Soc Exp Biol , 2019. Vol. 33, no 12, p. 14394-14409
Keywords [en]
osteoporosis, bone resorption, calcium-regulating hormones, osteoclasts
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:umu:diva-167633DOI: 10.1096/fj.201802729RRRISI: 000507466100103PubMedID: 31675485Scopus ID: 2-s2.0-85076062407OAI: oai:DiVA.org:umu-167633DiVA, id: diva2:1391058
Available from: 2020-02-03 Created: 2020-02-03 Last updated: 2020-02-03Bibliographically approved

Open Access in DiVA

fulltext(2131 kB)22 downloads
File information
File name FULLTEXT01.pdfFile size 2131 kBChecksum SHA-512
a9a02da248a240d1c46e8aea1e8e12abf62909f3891fc95bc3e8f841ebda9075b7ee352cc86cc803efcd400f310c9d5b3256d2e32a35c33518544bfbb9cd6d7b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lie, AntiaLerner, Ulf H.
By organisation
Department of Odontology
In the same journal
The FASEB Journal
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 22 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 24 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf